Organigram Earnings: Canaccord Raises Target While Others Cut
On April 13th, Organigram Holdings (TSX: OGI) (NASDAQ: OGI) reported their second fiscal quarter for 2021. Revenue for the quarter
Read more
Analyst Estimate
Aphria: The Analyst Take On Q3 Results
On April 12th, Aphria Inc (TSX: APHA) (NASDAQ: APHA) released its fiscal third quarter results. The company reported net revenues
Read more
Tesla: Canaccord Doubles Price Target To $1,071
On Monday, one of the more bearish Tesla Inc. (NASDAQ: TSLA) analysts flipped bullish, and more than doubled their 12-month
Read more
MicroStrategy: Canaccord Initiates With $920 Price Target
On Friday, Canaccord Genuity initiated coverage on MicroStrategy (NASDAQ: MSTR) with a $920 price target and buy rating. Joseph Vafi,
Read more
Verano Holdings: Canaccord Reiterates $35 Price Target
On April 8th, Verano Holdings (CSE: VRNO) announced their full year 2020 and fourth quarter results, with the results being
Read more
Organigram: Consensus Analyst Estimates For Q2 2021
Organigram Holdings (TSX: OGI) (NASDAQ: OGI) will be reporting their fiscal second quarter on April 13th before the market open.
Read more
Curaleaf: The Analyst Take On The European Expansion
On April 7th, Curaleaf Holdings (CSE: CURA) announced that they completed $312 million acquisition of related party European company EMMAC
Read more
Raymond James Reiterates $6 Price Target On Organigram Holdings
On April 6th, Organigram Holdings (TSX: OGI) (NASDAQ: OGI) announced that they acquired cannabis 2.0 operator The Edibles & Infusions
Read more
Aphria: Consensus Estimates For Q3 2021
Aphria Inc (TSX: APHA) (NASDAQ: APHA) is expected to report their fiscal third quarter on April 12th. Analysts have a consensus
Read more
Greenlane: Canaccord’s Take On The KushCo Merger
On March 31st, Greenlane Holdings (NASDAQ: GNLN) announced their fourth quarter and full-year financial results. Additionally, they announced that they
Read more